Bleomycin electroporation therapy

Drug Profile

Bleomycin electroporation therapy

Alternative Names: NeoPulse; OMS ElectroChemotherapy; SECTA therapy; Selective Electrochemical Tumor Ablation therapy

Latest Information Update: 10 Oct 2011

Price : $50

At a glance

  • Originator Inovio Biomedical Corporation
  • Developer Inovio Pharmaceuticals
  • Class Antineoplastics; Cytostatic antibiotics; Glycopeptides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Breast cancer; Head and neck cancer; Malignant melanoma
  • Discontinued Basal cell cancer; Kaposi's sarcoma; Liver cancer; Pancreatic cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 28 Sep 2011 OncoSec plans to conduct further clinical studies, based on positive results from clinical trials in Head and neck cancer and Breast cancer
  • 26 Sep 2011 Final adverse events and efficacy data from a phase I trial in Breast cancer released by OncoSec Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top